Botulinum toxin type A dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Botulinum toxin type A is a large bacterial protein that works as an enzyme, not a peptide.
Evidence grade for Botulinum toxin type A: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 2 completed trials, 1,681 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 1,681
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands.
5 effects reported, 3 unwanted, 2 wanted, by people using it, not a trial
Goal pages: Injury, healing and recovery, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Botox is a bacterial toxin that quiets nerves. Tiny doses stop a muscle from moving or a gland from sweating. Most people know it for wrinkles. It has more medical uses, like migraine, bladder problems and stiff muscles.
What people take it for
- Smoothing frown lines and wrinkles.
- Preventing chronic migraine.
- Stopping heavy sweating.
- Some men use it for erection problems, which it is not approved for.
What studies in people showed
In 1384 adults with chronic migraine, headache days fell by 8.4 a month on the toxin. On dummy shots, they fell by 6.6. So the real gap is under two days a month. For frown lines, one study had 297 adults. At one month, 82.9 percent hit the target, against nobody on dummy shots. By six months, only 23.6 percent were still graded none or mild. It carries the FDA's strongest warning, about the toxin spreading.
What people report
Reports, not study results
The good
- Men using it for erection problems describe change within days, more morning erections, and needing less of their other shots.
- Some say the effect was still there at three months or later.
The bad
- The effect wears off and needs repeat shots, with less return each time.
- People warn against mixing it with other erection shots without cutting those doses first.
- Finding a doctor is hard, and people describe paying roughly 800 to 2,000 dollars a session.
Where these come from: Botulinum toxin threads on ExcelMale, as collected for this page. These lean positive, because people it did nothing for have less reason to write. The migraine and frown line numbers are from the studies on this page.
My bottom line
It works, and it wears off. It is not a peptide, and no cream copies it. Use a trained injector and nobody else.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Botulinum toxin type A has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Pain1,384 people · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Botulinum toxin type A, what they expect, and what goes wrong. The full account, including the negative reports, is below.
34 of the 36 indexed goals have no study of any kind behind Botulinum toxin type A
No study in people, animals or cells on this page reports a result for these. That does not prove Botulinum toxin type A does nothing for them. It does mean anything you have heard about Botulinum toxin type A and one of these did not come from a study cited here.
Show full evidence
What is Botulinum toxin type A?
Botulinum toxin type A is a large bacterial protein that works as an enzyme, not a peptide. It was first approved in 1991 and carries the FDA's strongest warning, about the toxin spreading beyond where it was injected. Its medical uses far outnumber its cosmetic ones. In pooled migraine studies of 1384 people, headache days fell 8.4 a month on the toxin and 6.6 on dummy shots. For wrinkles, results are graded on frown-line scales and last roughly 3 to 6 months.
Botulinum toxin type A is in this archive for one reason. Peptide creams such as argireline are sold as alternatives to it, and that comparison needs a true reference point. So start with what it is. It is a large protein, 150 kDa, made by the bacterium Clostridium botulinum. That is about eighty times heavier than a typical peptide drug. It is an enzyme that cuts up its target inside the nerve ending. A six-part peptide in a cream would have to get through the skin's outer layer and reach a nerve ending that moves a muscle. It is not a weaker version of this. It is a different kind of thing, and the strength gap is enormous.
Botox was approved on 9 December 1991, decades before the cosmetic use most people know. Its medical uses outnumber its cosmetic ones. They include preventing chronic migraine, overactive bladder, bladder problems from nerve damage, stiff arm and leg muscles in adults and children, a twisting neck condition, heavy underarm sweating, eyelid spasms, and crossed eyes. The cosmetic approvals cover frown lines, crow's feet, forehead lines and neck bands.
All botulinum products carry the FDA's strongest warning, about the toxin's effect spreading. After approval, reports came in of symptoms like botulism, including trouble swallowing and breathing. They showed up hours to weeks after the shot. Some were fatal, most often in children treated for stiff muscles. That warning covers the cosmetic products too.
The cosmetic evidence is strong on its own terms, and it is worth knowing what those terms are. Results are graded on wrinkle scales, at full frown, by both a doctor and the person. In READY-1, a study of 297 adults, 82.9 percent hit the combined mark at month 1, against 0 percent on dummy shots. By month 6, 23.6 percent of treated people were still graded none or mild, against 1.5 percent. That is the honest picture of how long it lasts.
How does Botulinum toxin type A work?
One half of the toxin grabs onto nerve endings that control muscles and glands, and the toxin gets pulled inside. The other half is an enzyme. It cuts a protein called SNAP-25. Nerve endings need SNAP-25 to release their chemical messenger. Without it, the message never gets out, and the muscle or gland goes quiet. Because it is an enzyme, a tiny number of toxin molecules can cut a huge number of SNAP-25 targets. That is why it is so strong. Recovery takes months. It depends on the nerve growing new endings and making new SNAP-25, not on the body clearing the drug.
What have studies in people found about Botulinum toxin type A?
One of the most tested shots in medicine. There is a medical program in migraine, bladder, stiff muscles and neck twisting, and a separate cosmetic program in facial lines. The cosmetic results are graded on wrinkle scales at full expression, and the effect wears off.
- Pooled migraine studies, 1384 adults with chronic migraine: headache days at week 24 fell 8.4 a month on the toxin and 6.6 on dummy shots.
- READY-1, 297 adults, frown lines: 82.9 percent hit the combined mark at month 1, against 0 percent on dummy shots.
- READY-1 at month 6: 23.6 percent still graded none or mild, against 1.5 percent. So most of the effect is gone by then.
- Side effects blamed on treatment in READY-1 were 3.6 percent and usually mild, in healthy adults having cosmetic shots.
- The FDA's strongest warning, about the toxin spreading, covers every type A product, cosmetic ones included.
What this does not tell you: Cosmetic results are graded by a doctor and the person, on wrinkle scales at full frown. Those are judgment calls. They do not measure how a face looks at rest or how other people see it. The effect is temporary, roughly 3 to 6 months. Cosmetic studies take healthy adults, so they say nothing about risk in people with nerve or muscle disease, where the warning matters most. A few people stop responding after repeated shots because their body makes antibodies. The cosmetic research barely measures how often. Units are not the same between brands, so comparing doses across brands takes care.
What do people who took Botulinum toxin type A report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Almost all the first-hand discussion reachable in these communities is about injection into cavernous tissue for erectile dysfunction, not about cosmetic or longevity use. The cosmetic threads carry detail on how the toxin acts and what can go wrong but contain no personal accounts at all, and the other clinical threads are study summaries with no experience attached.
- Amounts described are 50 to 100 units in total, given as four injections of 25 units, and people compare the discomfort to standard intracavernous injections they already do.
- What people describe is change within days rather than the delay usual for cosmetic use, more spontaneous and morning erections, and needing substantially less of their existing injectable erection drugs. Accounts written at three months and beyond describe the effect still present.
- The effect is described by the same people as temporary and needing repeat treatment, with less return each time. A specific warning recurs about combining it with existing injectable erection drugs without cutting those doses first. Finding a clinician willing to do it is described as a real obstacle, and cost is described in the range of roughly 800 to 2,000 dollars a session.
- Scepticism appears inside the same threads, aimed at marketing claims of size increase, which posters say has nothing behind it. The study threads separately note that the trials are small, that the effect fades by about three months, and that there is no long-term data on scarring.
- These accounts skew positive for an obvious reason: they come from people who sought out an unapproved procedure and paid for it privately, and the people it did nothing for have less reason to write it up.
Sources: Botulinum toxin threads on ExcelMale covering intracavernosal use, the underlying study literature and cosmetic injection, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
The state of the research
This page sits in a peptide archive because of the argireline comparison, and it deserves to be spelled out.
Argireline is a chain of six building blocks, put on the skin as a cream. The idea is that it gets in the way of the machinery nerve endings use to release their messenger. Botulinum toxin type A is a large injected enzyme that cuts SNAP-25 inside the nerve ending. A handful of toxin molecules can knock out a huge number of targets. For a peptide cream to do anything close, it would need to get through the skin's outer layer in bulk and reach a nerve ending that moves a muscle. They are not the same action at different strengths. They are different kinds of treatment, and the strength gap is enormous.
The second point is how big the medical side is. Most people meet this drug as a wrinkle treatment, and most coverage stops there. Its bigger evidence base is in chronic migraine, overactive bladder, stiff muscles, neck twisting and heavy sweating. There the shots are bigger, the doses higher, and the warning about spread matters most. The cosmetic use is the small, visible corner of a much bigger drug.
The evidence, in charts
Fig. 1a · how many people
1,681people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Headache 2010 | 1,384 | 82% |
| Aesthetic Surgery Journal 2024 | 297 | 18% |
One study holds 82% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 sources here are studies in people. The rest is not.
- Study in people · done in people375%
- Review of studies · sums up other studies125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2010 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- About 150 kDa. A bacterial protein and an enzyme, not a peptide by any useful definition.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not a meaningful plasma measure. The drug acts locally and is not detectable systemically at therapeutic doses; the duration of effect reflects how long it takes nerve terminals to regenerate, which is typically several months.
No amino acid sequence is on file for Botulinum toxin type A, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2010OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program
Botulinum toxin cut chronic migraine days, and the dummy injections cut them almost as much. 1,384 adults were injected with either the toxin or a dummy every twelve weeks across two trials. After six months, headache days had fallen by about eight a month on the toxin and about seven on the dummy. The gap between them is under two headache days a month. That gap is real and it held at every check. It is also far smaller than the raw drop people quote.
The therapeutic evidence that is usually left out of cosmetic coverage. Two multicentre phase 3 trials pooled, 1384 adults randomised 1 to 1 to onabotulinumtoxinA 155 to 195 units or placebo every 12 weeks. Mean change in headache days at week 24 was minus 8.4 versus minus 6.6 in favour of the toxin, P below 0.001, with significant differences at all other timepoints. Note that placebo also produced a large decrease, so the between-group difference is under two headache days per month.
- Study in people2024Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines
A ready mixed liquid botulinum toxin smoothed frown lines on the scales used to grade them. 297 adults got either the new formulation or a dummy injection and were followed six months. At one month, more than eight in ten treated people met the strict combined improvement mark, against nobody on the dummy. Almost every treated face was graded none or mild when frowning. By six months that had fallen to about one in four. Side effects blamed on treatment were uncommon and usually mild.
297 adults randomised 3 to 1 to relabotulinumtoxinA 50 units or placebo, followed 6 months. Co-primary endpoints at month 1 at maximum frown: composite response of at least 2 grades improvement on both investigator and participant scales 82.9 percent versus 0 percent, and investigator-rated none or mild 96.3 percent versus 4.5 percent, both P below 0.001. At month 6, investigator-rated none or mild had fallen to 23.6 percent versus 1.5 percent. Treatment-related adverse events 3.6 percent, typically mild.
- Study in people2010A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
A registry record rather than a result. This is one of the two trials later published together as the migraine programme, so the numbers people quote come from the pooled paper and not from here. The record is marked completed and it enrolled 679 people. It sits on this page so the trail can be followed.
One of the two registered PREEMPT trials. Status COMPLETED, actual enrolment 679. Included to make the therapeutic programme traceable, since the pooled publication reports both trials together.
- Review of studies2023Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials
A review that pooled frown-line studies to compare different type A brands. It is useful for comparing brands. It also reminds you that units differ between brands and cannot be converted, so comparing doses across brands is not simple.
A network meta-analysis comparing type A products in glabellar lines. Useful as the cross-product comparison, and a reminder that units differ between brands and cannot be converted, so dose comparisons across products are not straightforward.
Common questions
Has Botulinum toxin type A been tested in people?
Yes. 1,681 people given it across 2 completed trials cited here, 0 of which found nothing. Botulinum toxin type A is a large bacterial protein that works as an enzyme, not a peptide.
What is the Botulinum toxin type A dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands.
Is Botulinum toxin type A FDA-approved?
FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands.
Is botulinum toxin a peptide?
No. It is a large bacterial protein and an enzyme, about eighty times heavier than a typical peptide drug. It is covered here because peptide creams are marketed against it, and the comparison needs a true reference point.
Can a topical peptide do what Botox does?
No. Botulinum toxin is injected, and it works as an enzyme, destroying SNAP-25 inside the nerve ending. So a tiny amount has a big, lasting effect. A peptide cream would have to get through the skin's outer layer and reach a nerve ending that moves a muscle to do anything at all. The strength gap is enormous. They are different kinds of treatment, not the same one at different strengths.
Does it carry a boxed warning?
Yes. Every type A product carries the FDA's strongest warning, about the toxin's effect spreading. It describes reports of botulism-like symptoms, including trouble swallowing and breathing, hours to weeks after a shot. A few were fatal, most often in children treated for stiff muscles. The warning covers cosmetic products too.
How long does it last?
Roughly 3 to 6 months, and you can see it fade in the study data. In READY-1, 96.3 percent were graded none or mild at month 1, and 23.6 percent at month 6. Recovery depends on nerve endings regrowing, not on the drug leaving the body.
What is it actually approved for besides wrinkles?
Preventing chronic migraine, overactive bladder, bladder problems from nerve damage, stiff arm and leg muscles in adults and children, a twisting neck condition, heavy underarm sweating, eyelid spasms, and crossed eyes. The medical list is much longer than the cosmetic one, and it came first. The first approval dates to 1991.
Are Botox, Dysport and Xeomin interchangeable?
Not by dose. Each maker measures units with its own test, and units do not convert between brands. So swapping one brand for another unit for unit is unsafe. The only fair way to compare them is a review that pools the frown-line studies across brands.